Document is current

Article History

Received: 30 September 2025

Accepted: 31 December 2025

First Online: 23 January 2026

Declarations

:

: The study received approval from the ethical review board of LMU (approval no.17–656, 604 − 16) and was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent prior to each [18 F]FET PET/CT scan which was performed as part of clinical routine.

: The patient provided written informed consent to publication of this report.

: MJM has received research funding from Bristol-Myers Squibb and travel support from Pierre Fabre. SCK was supported by the BZKF (Bayerisches Zentrum für Krebsforschung). MP has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen, Adastra, Gan & Lee Pharmaceuticals, Janssen, Servier, Miltenyi, Böhringer-Ingelheim, Telix, Medscape, OncLive, Medac, Nerviano Medical Sciences, ITM Oncologics GmbH. NLA has received honoraria for lectures, consultation or advisory board participation from Novartis / Advanced Accelerator Applications, ABX, ITM Oncologics GmbH, Carthera, Medsir, Telix Pharmaceuticals, Servier and OncLive and research funding from Novocure, Servier and Telix Pharmaceuticals.